阿米三嗪-萝巴新治疗阻塞性睡眠呼吸暂停低通气综合征的临床研究  

Clinical research on obstructive sleep apnea-hypopnea syndrome treated with Almitrine-raubasine

作　　者：王娟[1] 曹洁[1] 陈宝元[1] 王彦[1] 郭美南[1] 

机构地区：[1]天津医科大学总医院呼吸科,天津300052

出　　处：《中国现代医学杂志》2011年第29期3639-3642,共4页China Journal of Modern Medicine

摘　　要：目的探讨阿米三嗪-萝巴新应用于阻塞性睡眠呼吸暂停低通气综合征患者的可能性。方法 30例入选患者均口服都可喜(每片含阿米三嗪30 mg,萝巴新10 mg),比较治疗前后相关指标的变化。结果 30例患者应用阿米三嗪-萝巴新后,夜间最低血氧饱和度提高,同时使重度阻塞性睡眠呼吸暂停低通气综合征患者的日间血氧分压及血氧饱和度升高;治疗后中度组最大吸气压及最大呼气压均较前增高;对夜间呼吸事件没有明显改善。结论阿米三嗪-萝巴新可能改善阻塞性睡眠呼吸暂停低通气综合征患者的缺氧状况,另外可能有改善部分患者呼吸肌功能的作用。[Objective] To investigate the effects of Almitrine-raubasine on the patients of OSAHS. [Methods] Duxil （30rag Almitrine and 10 mg Raubasine per pill） was used in 30 patients and some index were measured before and after the use of Duxil. [Results] After the use of Almitrine-raubasine, nighttime MinSa02 increased in all patients, daytime PaO： and SaO： increased in severe patients and both MIP and MEP increased in some patients, but the respiratory event did not change. [ Conclusions] Almitrine-raubasine can improve hypoxemia in the patients of OSAHS, and can improve the function of respiratory muscle in some patients of OSAHS.

关 键 词：阿米三嗪-萝巴新 阻塞性睡眠呼吸暂停低通气综合征 低氧血症 

分 类 号：R56[医药卫生—呼吸系统] R962[医药卫生—内科学]